IndustryCompany release

Iovance lifts 2026 revenue guidance to $410M-$420M as Amtagvi reaches over 100 centres

🇺🇸 Iovance Biotherapeutics, Inc. (IOVA) · Thu 05 Nov 2026

The US cell therapy company reported about $122M in third-quarter revenue and raised its full-year outlook from $350M-$370M, citing growth in Amtagvi treatment sites.

Iovance Biotherapeutics has raised its 2026 revenue guidance to between $410M and $420M, up from the previous range of $350M-$370M. The update appears in a corporate presentation issued on 5 November 2026, which also reports third-quarter revenue of about $122M.

The company said it had more than 100 authorised treatment centres as of 5 November 2026. Those sites administer Amtagvi (lifileucel), its cell therapy product.

On finances, Iovance reported cash of about $382M at 30 September 2026. It says this is enough to fund operations well into 2029.

The presentation also covers Amtagvi approvals in several markets and a potential approval in the first quarter of 2027. It notes planned submissions in 2027 and label-expansion trials in lung cancer, sarcoma and endometrial cancer. The summary available does not specify which markets or indications the potential Q1 2027 approval and the 2027 submissions relate to.

What it means for your team

  • Market-access teams should note the growing number of authorised treatment centres, which is a key factor in patient access to Amtagvi.
  • Regulatory teams can track the potential first-quarter 2027 approval and the planned 2027 submissions, although the available details on markets and indications are limited.
  • Label-expansion trials in lung cancer, sarcoma and endometrial cancer point to possible future widening of the product's use beyond its current approved indications.

Company's press release (SEC filing): Iovance Biotherapeutics, Inc. ↗

Article written by VigiEye from the official source (Iovance Biotherapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →